BACKGROUND INFORMATION ON THE PROCEDURE 
1.  Submission of the dossier 
The  applicant  Swedish  Orphan  International  AB  submitted  on  06  June  2003  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised 
procedure for Orfadin, which was designated as an orphan medicinal product. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof. Giuseppe Nisticó  
Co-Rapporteur: Dr Jens Ersbøll  
Orphan Drugs: 
An  Orphan  Drug  status  was  granted  on  29  December  2000  (EU/3/00/012)  to  Swedish  Orphan 
International  AB  for  use  of  nitisinone (Orfadin) in the following indication: Treatment  of  hereditary 
tyrosinemia type 1. The calculated prevalence of this condition was 0.1 per 10,000 EU population. 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
Orfadin has been given a Marketing Authorisation in United States on 18 January 2002. 
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 06 June 2003.  
The procedure started on 21 July 2003. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  30 
September  2003.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 30 September 2003. 
During  the  meeting  on  18-20  November  2003,  the  CHMP agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  20 November 2003. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 13 May 
2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  25 June 2004. 
During the CHMP meeting on 27-29 July 2004, the CHMP agreed on a list of outstanding issues 
to be addressed in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues on 01 October 2004. 
The Rapporteurs circulated the revised Joint Assessment Report on 05 November 2004.  
During  the  meeting  on    15-18  November  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  Orfadin  on  18 
November 2004. The applicant provided the letter of undertaking on the specific obligations and 
follow-up measures to be fulfilled post-authorisation on 18 November 2004. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 21 February 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
